A Chinese scientist reviewing laboratory equipment

Research news

This section contains news items that were not issued as a press release.

Monday, 11 March 2013
AstraZeneca responds to report on antimicrobial resistance Today’s report Infections and the rise of antimicrobial resistance from England's Chief Medical Officer is a powerful reminder of the global threat to public health that the rise in drug-resistant bacteria represents.
Thursday, 28 February 2013
AstraZeneca and Exco InTouch to develop real-time disease management tool for patients with chronic conditions AstraZeneca and Exco InTouch to develop real-time disease management tool for patients with chronic conditions
Tuesday, 12 February 2013
AstraZeneca and Russia’s Petrov Institute sign cancer research collaboration AstraZeneca and the N.N. Petrov Institute of Oncology, one of Russia’s leading cancer research institutions, today announced a research collaboration to identify genetic mutations in cancer patients
Monday, 11 February 2013
New IMI projects to revitalise antibiotic development New Drugs 4 Bad Bugs programme represents an unprecedented partnership between industry, academia and biotech organisations to combat antibiotic resistance in Europe.
Thursday, 7 February 2013
€196 million pan-European drug discovery platform launched Large pharmaceutical companies join forces with small and medium-sized enterprises (SMEs) and academia in an IMI-supported public private partnership (PPP) to enhance early drug discovery and so address the ever-increasing need for innovative therapeutics to tackle unmet medical needs
Friday, 25 January 2013
LDC forms drug discovery alliance with AstraZeneca Dortmund, January 24, 2013 – The Lead Discovery Center GmbH (LDC) and AstraZeneca have joined forces to discover new medicines for the treatment of human diseases with high unmet medical need.
Tuesday, 15 January 2013
AstraZeneca announces changes to Senior Executive Team AstraZeneca today unveiled changes to its executive leadership team. The new, expanded membership of AstraZeneca’s Senior Executive Team, which comes into effect immediately, includes increased representation of the company’s scientific expertise, key products and key markets.
Monday, 14 January 2013
AstraZeneca and Vanderbilt University collaborate to develop novel treatments for major brain disorders AstraZeneca and Vanderbilt University collaborate to develop novel treatments for major brain disorders.
Thursday, 3 January 2013
Cellular Dynamics announces agreement with AstraZeneca on use of iPSC-derived human cells in drug discovery research Cellular Dynamics International, Inc. (CDI) today announced a Center of Excellence agreement with AstraZeneca to accelerate the pace of drug discovery through the use of human induced pluripotent stem cell (iPSC) lines and tissue cells.
Thursday, 27 December 2012
CytImmune and AstraZeneca to Research Potential New Nanomedicine Rockville, MD and Waltham, MA –December 27, 2012-CytImmune and AstraZeneca have entered into an agreement to study the feasibility of a new cancer nanomedicine that will bind an oncology compound from AstraZeneca to CytImmune’s CYT-6091 nanomedicine platform.